MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Merck & Co Inc.

Închisă

SectorSănătate

86.61 -0.51

Rezumat

Modificarea prețului

24h

Curent

Minim

85.39

Maxim

87.02

Indicatori cheie

By Trading Economics

Venit

583M

3.7B

Vânzări

-1B

16B

P/E

Medie Sector

13.318

63.778

EPS

1.72

Randament dividend

3.61

Marjă de profit

23.963

Angajați

73,000

EBITDA

1.3B

6.9B

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+28.42% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

3.61%

2.39%

Următoarele câștiguri

24 apr. 2025

Data viitoare de dividende

7 apr. 2025

Următoarea dată ex-dividende

16 iun. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-26B

227B

Deschiderea anterioară

87.12

Închiderea anterioară

86.61

Sentimentul știrilor

By Acuity

39%

61%

145 / 386 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

Merck & Co Inc. Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

4 feb. 2025, 12:33 UTC

Câștiguri

Merck 4Q Earnings Rise; 2025 Outlook Hits Shares -- Update

4 feb. 2025, 11:57 UTC

Câștiguri

Merck 4Q Sales Increase Results in Swing to Profit

24 mar. 2025, 05:00 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Chipotle and 4 More Buyback Stocks for a Down Market -- Barrons.com

5 mar. 2025, 19:42 UTC

Top știri

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- Update

5 mar. 2025, 10:30 UTC

Top știri

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- WSJ

5 feb. 2025, 12:00 UTC

Top știri

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

4 feb. 2025, 14:48 UTC

Câștiguri

Merck Stock Plummets 10% As Gardasil Dynamics, 2025 Guidance Weigh On Shares -- IBD

4 feb. 2025, 11:51 UTC

Câștiguri

Merck's Soft Guidance Offsets Better-Than-Expected Fourth-Quarter Earnings -- MarketWatch

4 feb. 2025, 11:50 UTC

Câștiguri

Merck Stock Tumbles on Weak Guidance and Gardasil Sales Slump -- Barrons.com

4 feb. 2025, 11:31 UTC

Câștiguri

Merck 4Q Gardasil/Gardasil 9 Sales Down 17% >MRK

4 feb. 2025, 11:31 UTC

Câștiguri

Merck 4Q Gardasil/Gardasil 9 Sales $1.55B >MRK

4 feb. 2025, 11:31 UTC

Câștiguri

Merck 4Q Januvia/Janumet Sales Down 38% >MRK

4 feb. 2025, 11:31 UTC

Câștiguri

Merck 4Q Januvia/Janumet Sales $487M >MRK

4 feb. 2025, 11:30 UTC

Câștiguri

Merck 4Q Keytruda Sales Up 19% >MRK

4 feb. 2025, 11:30 UTC

Câștiguri

Merck 4Q Keytruda Sales $7.84B >MRK

4 feb. 2025, 11:30 UTC

Câștiguri

Merck 4Q Pharmaceutical Sales Up 7% >MRK

4 feb. 2025, 11:30 UTC

Câștiguri

Merck 4Q Pharmaceutical Sales $14.04B >MRK

4 feb. 2025, 11:30 UTC

Câștiguri

Merck Sees FY Adj EPS $8.88-Adj EPS $9.03 >MRK

4 feb. 2025, 11:30 UTC

Câștiguri

Merck: Anticipate Strong Growth in Back Half of 2025, as Well as in Both 2026 and 2027 >MRK

4 feb. 2025, 11:30 UTC

Câștiguri

Merck Sees FY Rev $64.1B-$65.6B >MRK

4 feb. 2025, 11:30 UTC

Câștiguri

Merck: Believe Temporary Pause Will Facilitate a More Rapid Reduction of Excess Inventory >MRK

4 feb. 2025, 11:30 UTC

Câștiguri

Merck: Expect Strength in Oncology and Contributions From Ongoing and New Launches of Important Products in Both Human and Animal Health Businesses to More Than Offset GARDASIL Headwind >MRK

4 feb. 2025, 11:30 UTC

Câștiguri

Merck 4Q Adj EPS $1.72 >MRK

4 feb. 2025, 11:30 UTC

Câștiguri

Merck: Gardasil Market Dynamics in China Do Not in Any Way Diminish the Confidence Co. Has in the Business >MRK

4 feb. 2025, 11:30 UTC

Câștiguri

Merck 4Q Net $3.74B >MRK

4 feb. 2025, 11:30 UTC

Câștiguri

Merck: Excluding Sales of Gardasil in China in Both 2024 and 2025, Expect Strong 2025 Growth Between 7%-9% (Ex-FX) Driven by Continued Strength in Oncology and Animal Health as Well as Contributions From New Product Launches >MRK

4 feb. 2025, 11:30 UTC

Câștiguri

Merck: Sales Outlook Reflects Reassessment of Market for Gardasil/Gardasil 9 in China and Decision to Temporarily Pause Shipments Until at Least Mid-Year >MRK

4 feb. 2025, 11:30 UTC

Câștiguri

Merck Sees FY25 Sales $64.1B-$65.6B >MRK

4 feb. 2025, 11:30 UTC

Câștiguri

Merck: Decline in 4Q Januvia/Janumet Sales Primarily Due to Lower Pricing in U.S., and Ongoing Generic Competition in Many International Markets and Supply Constraints in China >MRK

4 feb. 2025, 11:30 UTC

Câștiguri

Merck 4Q Winrevair Sales $200M >MRK

Comparație

Modificare preț

Merck & Co Inc. Așteptări

Obiectiv de preț

By TipRanks

28.42% sus

Prognoză pe 12 luni

Medie 111.88 USD  28.42%

Maxim 138 USD

Minim 95 USD

În baza a 17 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruMerck & Co Inc. - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

17 ratings

11

Cumpărare

6

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

87.08 / 93.84Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

Bullish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

145 / 386 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.